Tuesday, October 4, 2022


Biotechnology News Magazine

Cemvita Factory Grows Executive Team, Biofoundry Leadership

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Cemvita Factory (“Cemvita”), the leading provider of low-carbon biotech and synthetic biology solutions for the energy and mining industries, has announced the addition of Charles Nelson as Chief Business Officer, the promotion of Roger A. Harris to Chief Commercial Officer, and the recruitment of Alex Juminaga as Head of Strain Development, while also doubling the size of its Houston laboratory––moves to further the company’s plans for rapid scaling and commercialization.

Cemvita Factory advises a longtime leader in the field of carbon utilization with 10+ years in product development, engineering, and technology commercialization, Charles Nelson will oversee all aspects of sales, business development, and customer success. Roger A. Harris joined Cemvita as VP of Technology Commercialization in April of 2021 with 20+ years in research and development, and engineering. In his new role as Chief Commercial Officer, Harris is responsible for scaling and commercializing Cemvita’s technology.

Alex Juminaga will lead the Cemvita Factory biofoundry’s production of novel biomolecules. Juminaga brings 10+ years of laboratory experience to the team, specializing in metabolic engineering, protein expression/purification, enzyme kinetics and binding assays, analytical chemistry, and more.

“Scaling to meet market demand requires the right team at the right time,” says Tara Karimi, co-founder and CTO of Cemvita Factory. “With Charlie, Roger, and Alex’s leadership, we’re well-positioned for growth at a time when the demand for decarbonization solutions is greater than ever.”

“At Cemvita, we create sustainable solutions to challenges across heavy industries,” says Nelson. “Our goal is to reinvent heavy industries in ways that speak to the future, reduce companies’ carbon footprints, and even create jobs; I’m delighted to help lead the charge.”

“Cemvita is positioned incredibly well to support heavy industry in efforts to innovate, and to help oil and gas diversify offerings and reduce dependency on carbon-intensive products,” says Harris. “It is an exciting time and I’m thrilled to be with Cemvita.”

“The field of synthetic biology is just getting started, with thousands of microbes yet to be discovered,” says Juminaga. “I’m excited to work alongside the brilliant scientists at Cemvita as we uncover new microbiomes and new uses for these tiny treasures.”

With the expansion of its facilities, Cemvita has more space for research and development, enabling it to scale, adding more microbes to its current library and improving efficiency. “A complex problem like climate change cannot depend on one singular solution,” says Moji Karimi, co-founder and CEO of Cemvita. “Our platform is enabling our clients to decarbonize while creating new revenue streams, and we’re just getting started.”

To build on its current momentum, Cemvita Factory has expanded its talent pool throughout the past quarter and plans on closing a large Series B funding round this fall to finance its next phase of growth.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine